These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19137123)

  • 1. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
    Buzdar AU
    Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
    Chia S; Gradishar W
    Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer.
    Oakman C; Moretti E; Santarpia L; Di Leo A
    Future Oncol; 2011 Feb; 7(2):173-86. PubMed ID: 21345137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
    Croxtall JD; McKeage K
    Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
    Buzdar AU
    Drugs Today (Barc); 2004 Sep; 40(9):751-64. PubMed ID: 15538548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of fulvestrant ("Faslodex").
    Howell A
    Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
    Howell A
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new estrogen receptor antagonist--an overview of available data.
    Jones SE
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S19-21; discussion S33-5. PubMed ID: 12353819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
    Morris C; Wakeling A
    Endocr Relat Cancer; 2002 Dec; 9(4):267-76. PubMed ID: 12542403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulvestrant antiestrogen for treatment of breast cancer.
    Hancock CM
    Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    Abram P; Maass N; Rea D; Simon SD; Steger GG
    Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant - a novel endocrine therapy for breast cancer.
    Johnston SJ; Cheung KL
    Curr Med Chem; 2010; 17(10):902-14. PubMed ID: 20156170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant and the sequential endocrine cascade for advanced breast cancer.
    Johnston S
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S15-8. PubMed ID: 15094760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.